+ T cell responses. Nanoparticles, including virus-like particles (VLPs), are attractive candidates as carriers for vaccines and drug delivery. Using RNA phage Qb-derived VLP (Qb-VLP) as a model antigen, we found that antigen-specific B cells were the dominant antigen-presenting cells that initiated naive CD4 + T cell activation. B cells were sufficient to induce T follicular helper cell development in the absence of DCs. Qb-specific B cells promoted CD4 + T cell proliferation and differentiation via cognate interactions and through Toll-like receptor signaling-mediated cytokine production. Antigen-specific B cells were also involved in initiating CD4 + T cell responses during immunization with inactivated influenza virus. These findings have implications for the rational design of nanoparticles as vaccine candidates, particularly for therapeutic vaccines that aim to break immune tolerance.
INTRODUCTION
The initiation of adaptive immune response depends on simultaneous sensing of both foreign antigens and innate signals (Medzhitov and Janeway, 2002) . The discovery of dendritic cells (DCs) as antigen-presenting cells (APCs) and Toll-like receptors (TLRs) as pathogen-associated molecular pattern (PAMP) recognition receptors (PRRs) established our current understanding on how the adaptive immune system, especially T cells, are initiated and regulated by the innate immune system. In particular, DCs play central roles in the initiation of both CD4 + and CD8 + T cell activation by presenting antigens in the context of major histocompatibility complexes (MHCs) and producing cytokines to regulate T cell differentiation (Banchereau and Steinman, 1998; . B cells, in addition to their function in antibody production, also express high level of MHC class II and can present antigens to CD4 + T cells. It is known that T-B cognate interaction is important for the differentiation of both germinal center (GC) B cells and follicular helper T (Tfh) cells (Crotty, 2011) . Antigen presentation by B cells is also critical in the pathogenesis of several autoimmune diseases (Serreze et al., 1998; Chan et al., 1999; Clark et al., 2004) . However, whether B cells can activate naive CD4 + T cells was a subject of debate. Subsequently, DCs were found capable of activating naive CD4 + T cells (Epstein et al., 1995; Topham et al., 1996) , and in parallel, it was found that only antigen-specific B cells can establish efficient cognate interaction with CD4 + T cells in vivo (Chesnut and Grey, 1981; Rock et al., 1984; Lanzavecchia, 1985) . As antigen-specific B cells are very rare before immunization compared to the more abundant DCs , it is currently thought that B cells contribute minimally to the initial activation of CD4 + T cells due to their scarcity and that B cells do not interact with CD4 + T cells until naive CD4 + T cells have been primed by DCs. Nanoparticles, due to their large surface area to volume ratio, often exhibit unique properties and have been widely explored as carriers for drug delivery or vaccines in the biomedical field (Gomes et al., 2017) . Multivalency is an important feature employed by many nanoparticle applications. For drug delivery, multivalency can increase the binding avidity to targeted cells or tissues. For vaccines, multivalency resembles the natural feature of viruses and can greatly boost the immunization efficacy. Nanoparticles assembled from viral coat proteins, termed virus-like particles (VLPs), are commonly used in these applications . However, despite the growing popularity of these bioreagents in medical use, our understanding of how they interact with the immune system in vivo is still very limited and is mainly based on the previous studies using traditional model antigens, such as soluble proteins. In particular, regarding nanoparticle vaccines, it has been assumed that these antigens are taken up by DCs to initiate the T cell response.
In this study, we found that the initial activation of CD4 + T cells in response to an RNA-phage-derived VLP did not require DCs. Instead, antigen-specific B cells acted as potent APCs to activate naive CD4 + T cells and promote their differentiation into Tfh cells. The GC response induced by this VLP was able to occur in the absence of DCs. Cognate antigen presented by B cells was required for the proliferation of CD4 + T cells, and the cytokine milieu generated by B cells in response to TLR signaling was required for the differentiation of CD4 + T cells.
B cells also acted as APCs during influenza virus-induced CD4 + T cell responses, and thus might represent an evolutionarily conserved pathway for defending against viral infections. Our finding that B cells act as the dominant APCs to initiate naive CD4 + T cell response under physiological conditions will provide insights for developing novel prophylactic and therapeutic vaccines.
RESULTS

Antigen-Specific CD4
+ T Cells Are Activated upon
Qb-VLP Immunization
Bacterial phage Qb-derived VLPs (Qb-VLPs) are assembled from a single type of monomers and contain nucleic acids inside (Kozlovska et al., 1993) . Previous studies demonstrated that Qb-VLPs induce both T cell-independent (TI) and T cell-dependent (TD) antibody responses, including a GC response in the absence of conventional adjuvants (e.g., alum or complete Freud's adjuvant) (Gatto et al., 2004; Liao et al., 2017) . The strong immunogenicity of Qb-VLPs relies on their encapsulated nucleic acids, either ssRNA naturally derived from the host bacteria or CpG containing oligodeoxynucleotides (CpG ODN) artificially incorporated, which serve as potent TLR7 or TLR9 ligands to enhance the immune response (Jegerlehner et al., 2007) . Although TLR signaling in DCs is critical in many immune responses, for Qb-VLP and several other viruse-induced responses, it is the TLR signaling in B cells that is responsible for the proper antibody response including the GC response (Browne, 2011; Hou et al., 2011; Walsh et al., 2012; Clingan and Matloubian, 2013; Rookhuizen and DeFranco, 2014; Tian et al., 2018) .
To explore how CD4 + T cells are activated in response to
Qb-VLP, we generated VLPs assembled from both the original Qb protein and a fusion protein of Qb and ovalbumin-derived peptide, which can be recognized by CD4 + TCR transgenic T cells (OT-II). About 10%-15% of the 180 monomers in the assembled VLPs were replaced with the fusion protein , which corresponded to $20-30 copies of the OT-II CD4 + T cell epitopes in each particle. This new type of VLPs was named Qb-Ova. The low percentage of the integration of the fusion protein allowed the preservation of the majority of the B cell epitopes in the original Qb-VLP, as demonstrated by the robust Qb-specific B cell response upon immunization with Qb-Ova ( Figure S1D ). For the purpose of comparison, we used the same mass of Qb-Ova for immunization as soluble monomeric ovalbumin (Ova), with the molar amount of OT-II CD4 + T cell epitopes in Qb-Ova being 1/3-1/2 of that in Ova.
To examine CD4 + T cell activation, we adoptively transferred was a robust expansion of OT-II CD4 + T cells, concurrently with extensive CFSE dilution in these cells, which was quantified as proliferation index to reflect the average cell division numbers ( Figures 1A and 1B) . In addition, surface marker CD44 was upregulated and CD62L was downregulated in a large fraction of CFSE-diluted cells, consistent with T cells being activated (Figure 1C) . To determine whether the activated CD4 + T cells could undergo further cell differentiation, molecules that are associated with or required for the differentiation of different Th cell lineages were examined. Both chemokine receptor CXCR5 and programmed cell death protein PD-1 were dramatically upregulated, and the transcription factor Bcl-6 was also upregulated in a fraction of OT-II CD4 + T cells (Figures 1D and S2A) , suggesting that these cells might be the precursors of GC Tfh cells. Qb-VLP actually induces strong GC response which peaks at $12d post-immunization (Gatto et al., 2004; Liao et al., 2017) . We noticed that Bcl-6 in the OT-II CD4 + T cells declined quickly from d3 to d7 ( Figure 1D ), although the CXCR5 + PD-1 + cells maintained at $20% throughout the response ( Figures S2A and S2B ). This phenomenon was also reported in a study using YFP reporter to monitor Bcl-6 expression. The decline of Bcl-6 is correlated with the reduced capability of cell proliferation in Tfh cells (Kitano et al., 2011) . In addition to Tfh cell-related markers, the transcription factor T-BET and its target gene chemokine receptor CXCR3 were also induced substantially in a large fraction of OT-II CD4 + T cells ( Figure 1E ), suggesting that Qb-Ova also induced CD4 + T cell differentiation toward Th1 cells. On the other hand, the expression of transcription factors GATA3, RORgt, and Foxp3 were not detected in these OT-II CD4 + T cells (data not shown). To rule out potential effects of clonal competition on CD4 + T cell activation, we examined OT-II CD4 + T cell proliferation and differentiation in the context of many fewer transferred cells and found no apparent effect (Figure S2C) . Thus, naive OT-II CD4 + T cells were activated efficiently upon Qb-Ova immunization. Since B cells require specific antigen receptors (BCRs) for bind-
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ing to antigens, we tested whether mice lacking BCRs that can bind to Qb-VLP might exhibit any defect in Qb-Ova-induced CD4 + T cell activation. We previously found that BCR transgenic mice (MD4), which express BCRs recognizing hen egg lysozyme (Goodnow et al., 1988) , contain very few Qb-specific B cells . Hence, we transferred naive OT-II CD4 + T cells into MD4 mice, followed by immunization and subsequent assessment of T cell activation at d3 post-immunization. Upon Qb-Ova immunization, there was a severe defect in the OT-II CD4 + T cell response in MD4 mice. In particular, OT-II CD4 + T cell expansion was greatly reduced ( Figure 3A) on antigen-specific B cells. In contrast, antigen-specific B cells were required for the Qb-Ova-induced CD4 + T cell activation. Using another BCR transgenic mouse line (Hy10), which harbors the same Ig heavy and light chain sequences as MD4 mice , we found no apparent defect of the CD4 + T cell activation ( Figure S3E ). Since Hy10 mice harbor higher percentages of B cells expressing endogenous recombined BCRs than MD4 mice do (data not shown), we wondered whether the difference of CD4 + T cell response in Hy10 and MD4 mice was correlated with the B cell response to Qb-VLP. Indeed, the number of Qb-specific B cells in Hy10 mice was much higher than that in MD4 mice following immunization ( Figure S3F ), consistent with our hypothesis that Qb-specific B cells are required for CD4 + T cell activation upon Qb-VLP immunization.
The fact that Hy10 mice exhibited $1/3 of Qb-specific B cells as WT mice while mounting near normal level of CD4 + T cell response suggested that antigen-specific B cells were highly efficient to mediate CD4 + T cell activation. Therefore, activation of naive OT-II CD4 + T cells upon Qb-Ova immunization seemed to depend on the existence of antigenspecific B cells.
DCs Are Not Required for the Initiation of CD4 + T Cell
Response Induced by Qb-VLP Although the result above suggested that DCs were not sufficient to initiate the CD4 + T cell response to Qb-Ova, it is possible that DCs are still required to prime the naive CD4 + T cells before B cells can act on these CD4 + T cells. To test this hypothesis, chimeric mice reconstituted from the bone marrow (BM) of CD11c-DTR-GFP mice, which express the fusion protein of diphtheria toxin (DT) receptor (DTR) and GFP under the CD11c promoter , were treated with DT before immunization. DCs were depleted efficiently upon DT treatment as expected ( Figure S4A ). However, from d2 post-immunization, due to the upregulation of CD11c in activated Qb-specific B cells (indicated by the upregulation of DTR-GFP and downregulation of IgD), DT treatment also depleted a large fraction of Qb-specific B cells, including GC B cells ( Figures S4B and S4C ). Therefore, we examined the effect of DC depletion on CD4 + T cell activation at 24 hr post-immunization, the time that DTR-GFP has not upregulated in Qb-specific B cells ( Figure S4C (B and C) Thy1.1 + cells from (A) are gated for the indicated markers.
Dots represent data from individual mice. Data were collected from at least three independent experiments. Mean ± SD is shown. Unpaired Student's t test was performed for statistical analysis. ns, non-significant, *p < 0.05, ***p < 0.001. See also Figure S3 .
depletion as expected, which also confirmed the efficacy of DT treatment ( Figures 4A-4C ). To determine whether this early activation of CD4 + T cells depended on antigen-specific B cells, we again transferred naive OT-II CD4 + T cells into MD4 mice, followed by immunization and subsequent assessment at 24 hr after immunization. As expected, the soluble Ova-induced CD4 + T cell response was not perturbed in MD4 mice. However, Qb-Ova-induced CD4 + T cell activation, especially the downregulation of CD62L and upregulation of CD25, was significantly reduced ( Figures 4D-4F ), which was in agreement with the defect of CD4 + T cell proliferation and differentiation in MD4 mice observed at d3 post-immunization (Figure 3) including PCs still developed well ( Figures S4D and S4E) . Hence, DCs seemed not essential for the Tfh cell development at any stages of Qb-VLP-induced response, whereas B cells could both initiate the activation of naive CD4 + T cells and promote the maturation of Tfh cells. The majority of the GC B cells (as well as PCs, not shown) in DT-treated mice were derived from the WT donor, in contrast with the very few WT-derived GC B cells in the untreated mice ( Figures S4D and S4E) , indicating that most Qb-specific GC B cells derived from the CD11c-DTR-GFP recipient mice were eliminated by DT treatment.
Therefore, DCs were completely dispensable for Qb-Ovainduced CD4 + T cell activation and Tfh cell development.
Qb-VLPs Are Captured by Antigen-Specific B Cells Effectively In Vivo Although the above results suggested a role of antigen-specific B cells in the initiation of CD4 + T cell response, it was still unclear how particulate antigens were captured by these B cells. To follow how Qb-VLPs encountered APCs after immunization, we injected intravenously (i.v.) AF647-labeled Qb-VLP (Qb-AF647) into mice and examined them 3 hr later. Despite the well-documented capability of DCs to take up particulate antigens such as sheep red blood cells (SRBCs) (Yi et al., 2015) , only a very low percentage of DCs exhibited Qb-AF647 binding in the spleen after Qb-AF647 injection ( Figure 5A ). In contrast, most Qb-AF647 + cells within MHCII + cells were B cells instead of DCs in the WT mice ( Figure 5B ). Moreover, within Qb-AF647 + MHCII + B cells, $5% exhibited high Qb-AF647 binding, which was likely to depend on BCRs, since high Qb-AF647-binding cells were absent in MD4 mice ( Figure 5B ). Both WT and MD4 mice contained B cells that bound to Qb-AF647 with low amount, suggesting that Qb-VLP might also bind to B cells through receptors other than BCRs. Indeed, it has been shown that Qb-VLP could be transported to B cell follicles in a complement-dependent manner (Link et al., 2012) . Consistent with this previous observation, we found that many B cells that bound to Qb-AF647 with low amount tended to be IgM hi (also IgD lo , not shown) marginal zone (MZ) B cells, which are known to express high amount of complement receptors. This phenomenon was more prominent at earlier time point (0.5 hr) after injection ( Figure 5C ). To explore whether MZ B cells could contribute to the antigen presentation through non-BCRmediated antigen uptake, Qb-AF647 + B cells were examined for CD83, a molecule upregulated upon B cell activation and involved in the posttranslational regulation of MHCII (Tze et al., 2011) . A small fraction of Qb-AF647 + B cells exhibited elevated CD83 after 0.5-3 hr of injection. However, most CD83 + cells
were IgD hi ( Figure 5C ), suggesting that MZ B cells were not preferentially activated by the antigen despite the fact that they were able to bind the antigen with low amount. Since antigen presentation by B cells greatly depends on the activation state of B cells, it was unlikely that MZ B cells were the predominant population that were directly involved in the cognate interaction with CD4 + T cells. However, MZ B cells might facilitate the antigen transport into B cell follicles by shuttling between MZ and follicle regions (Cinamon et al., 2008) . B1 B cells were also IgD lo and accounted for only a small fraction of Qb-specific B cells ( Figures  S5A and S5B ) and thus might not contribute to the CD4 + T cell activation much either.
We next examined whether B cells with high amount of Qb-AF647 binding exhibited any features in favor of antigen presentation. Since the frequency of these cells is very low ($0.04% in B cells), splenocytes from mice injected with Qb-AF647 were incubated sequentially with FITC-labeled Qb-VLP (Qb-FITC) followed with anti-FITC coupled magnetic beads to enrich Qb-AF647 + B cells. Within Qb-FITC-enriched B cells, a large fraction exhibited high amount of binding to Qb-AF647 (Figure 5D ). Since Qb-FITC + B cells include $50% of Qb + cells and $50% of FITC + cells (data not shown), this result suggested that the injected Qb-AF647 reached to almost all the Qb-specific B cells in spleen. The majority of these Qb-AF647 + B cells from the enriched fraction were CD83 + ( Figure 5D ), indicating efficient B cell activation upon Qb-VLP encounter. In addition, Qb-specific B cells enriched from mice immunized 24 hr before exhibited a significant upregulation of costimulatory molecule CD86 and chemotactic receptor CCR7 ( Figures 5E and 5F ), which presumably would enhance B cell antigen presentation and migration to T cell zones. Many other genes that are involved in antigen presentation and cytokine production were also differentially regulated in Qb-specific B cells at transcriptional level (Table S1 ). Their functions in promoting CD4 + T cell activation need further study. Unlike DCs which are located in T cell zone, B cells need to move out of B cell follicles before making contacts with CD4 + T cells. This extra migration step might delay B cell antigen presentation. To test this possibility, we compared the kinetics of CD4 + T cell activation in Qb-Ova and soluble Ova-immunized mice. CD69 was first upregulated within 3 hr of soluble Ova immunization, while Qb-Ova-induced response is still very limited ( Figures S5C and S5D ), suggesting that indeed CD4 + T cells made initial cognate interactions with DCs more quickly than with B cells. At later time points, there was no more difference of CD69 + % within OT-II CD4 + T cells between Qb-Ova and soluble Ova-immunized mice. Moreover, CD25, a marker indicating more advanced T cell activation state, although appearing a few hours later than CD69, was upregulated in a higher percentage of CD4 + T cells in Qb-Ova-immunized mice than in soluble Ovaimmunized mice ( Figure S5D ), suggesting that cognate B cells might provide a stronger stimulation to CD4 + T cells even the stimulation was slightly delayed.
In lymph nodes, it is suggested that CD169 + macrophages (Macs) could facilitate the transport of particulate antigens into B cell follicles (Cyster, 2010 ). We did not find an apparent association of Qb-VLP with CD169 + Macs in spleens ( Figures S5E   and S5F ). Removal of Macs by clodronate treatment also did not affect normal OT-II CD4 + T cell activation upon Qb-Ova immunization ( Figures S5G and S5H ), indicating that Macs were not essential for Qb-specific B cells to acquire antigen.
Thus, Qb-Ova-induced naive CD4 + T cell activation was preceded by B cell-mediated antigen capture and Qb-stimulated B cell activation. Bars represent the mean value. Dots represent the data from individual mice. Data were collected from three independent experiments. Unpaired Student's t test was performed for statistical analysis. ns, non-significant, **p < 0.01. See also Figure S5 . Dots represent data from individual mice. Data were collected from at least three independent experiments. Mean ± SD is shown. Unpaired Student's t test was performed for statistical analysis. ns, non-significant, *p < 0.05, **p < 0.01, ***p < 0.001. See also Figure S6 .
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(2013). In addition, the OT-II CD4 + T cells in MyD88 fl/fl CD79a-Cre mice exhibited a more prominent differentiation defect than proliferation defect (Figures 2A and 2B) , suggesting that factors produced downstream of B cell MyD88 signaling might promote CD4 + T cell differentiation. These factors presumably were intact in B-MHCII À/À mice and might promote CD4 + T cell differentiation even when the TCRs were only weakly activated. These hypotheses need to be tested in the future. Overall, although other APCs could provide some cognate stimulation to CD4 + T cells, B cells were the predominant APCs for Qb-Ova-induced naive CD4 + T cell activation.
Antigen-Specific B Cells Are Involved in the Initiation of CD4 + T Cell Response Induced by Influenza Viruses
So far, the mechanism we identified on how antigen-specific B cells initiated CD4 + T cell response applied specifically to VLP antigens, but not to soluble protein antigens. We hypothesized that this mechanism might be an evolutionarily conserved pathway for defending viruses, especially during viremia. It is known that DCs located in the peripheral tissue are important for the CD4 + T cell activation in response to locally applied antigens . However, in the case of viremia, viral antigens can travel directly to spleens and reach B cell follicles through sinuses and marginal zones. Thus, antigen-specific B cells, which also express TLRs for sensing viral nucleotides, might be extremely sensitive to blood-borne pathogens and are responsible for the initiation of the adaptive immune system. To test this idea, we used a modified strain of influenza A virus that carries the OT-II CD4 + T cell epitope (PR8-OVA) . Formalin-inactivated PR8-OVA was injected i.p. into WT or MD4 mice following OT-II CD4 + T cell transfer. Consistent with our hypothesis, MD4 mice exhibited a significant reduction in both CD4 + T cell expansion and T helper cell differentiation upon PR8-OVA immunization compared with WT mice ( Figures  7A and 7B ). When live PR8-OVA viruses were given, there was only a mild defect of CD4 + T cell activation in the MD4 mice (data not shown), suggesting that other APCs could compensate in bona fide viral infections. To test whether B cells were sufficient to activate naive CD4 + T cells in the absence of DCs, we immunized CD11c-DTR-GFP chimeric mice with inactivated PR8-OVA following OT-II CD4 + T cell transfer and DT treatment.
There was no difference of the CD4 + T cell activation between the control and DT-treated mice ( Figure 7C ), suggesting that DCs were not essential for influenza A virus-induced CD4 + T cell response. Thus, similarly to Qb-Ova, inactivated influenza viruses also induced naive CD4 + T cell activation through B cell antigen presentation.
Immunization with Qb-VLP Can Break Induced Immune Tolerance The immune system often employs redundant mechanisms during infections, so it may not be surprising that both DCs and B cells can incorporate innate signals with the antigen-presentation process to initiate the adaptive immune response. What could be the advantages to use B cells instead of DCs for antigen presentation? One advantage could be to increase the sensitivity to blood-borne viruses; the other advantage could be that B cells might be able to activate CD4 + T cells that are under tolerance control. It is suggested that regulatory T (Treg) cells exerted their regulatory functions through DCs. Treg cells could dampen DC functions by direct contact or by secreting IL-10 ( Shevach and Thornton, 2014) . We hypothesized that antigen presentation by B cells might provide a mechanism to bypass DC requirement in the situation when DCs are disabled by Treg cells. To test this hypothesis, we first induced immune tolerance to Ova in mice by supplying Ova in drinking water for 7 days consecutively. Ova-tolerized mice exhibited reduced antibody response upon immunization with Ova mixed with CpG ODN as expected ( Figure S7A ). We then transferred naive OT-II CD4 + T cells into these mice, followed by immunization and subsequent assessment at d3 post-immunization. Upon soluble Ova immunization, there was a moderate but significant reduction of both CD4 + T cell expansion and T helper cell differentiation in Ova-tolerized mice compared with the control mice ( Figures S7B and S7C) , consistent with the fact that Ova presentation by DCs was suppressed in the tolerized mice. In contrast, upon Qb-Ova immunization, the tolerized mice exhibited no difference from the control mice in all aspects of the CD4 + T cell activation ( Figures S7D and   S7E ), suggesting that antigen presentation by B cells could potentially break the immune tolerance mediated by DCs. The detailed mechanisms underlying how B cell antigen presentation could break CD4 + T cell tolerance needs further study.
DISCUSSION
In this study, we demonstrated that a nanoparticle antigen, Qb-VLP, could engage antigen-specific B cells for the initiation of CD4 + T cell response. Compared with DCs, the number of antigen-specific B cells under physiological conditions is much lower. We previously estimated that the number of Qb-specific B cells in each mouse spleen is $2 3 10 4 , which is two orders of magnitude lower than the number of total DCs ($3 3 10 6 ).
However, recent studies suggested that activation of T cells depends not only on the number of APCs, but also on the TCR signal strength provided by APCs (van Panhuys, 2016) . Indeed, even 1% of the regular number of DCs can still activate a large fraction of T cells when DCs are loaded with a high dose of antigen (Henrickson et al., 2008) . Since DCs capture antigens through non-specific binding, it will take high concentration of antigens to load DCs with high dose. (B and C) Thy1. (Cyster and Goodnow, 1995; Cyster, 2010) . The particulate nature per se of the antigen is not sufficient to explain the Qb-VLP-induced response either, since SRBC is a particulate antigen and uses DCs to activate CD4 + T cells (Yi et al., 2015) . Multivalency might be an important feature that distinguishes VLP antigens from soluble protein antigens. Multivalency may increase functional affinity between the antigen and antigen-specific B cells, allowing better capturing of the antigen by B cells. In addition, since antigen presentation by B cells is coupled to the activation of BCR signaling, multivalent antigens could induce stronger BCR signaling and hence enhance B cell antigen presentation (Clark et al., 2004) . It has been shown that multivalent antigens could promote more efficient antigen internalization and rearrangement of MHCII-containing antigen-processing compartments and could stimulate cognate CD4 + T cells better than their monomeric counterparts in vitro (Kim et al., 2006) . Multivalency may also lower the affinity threshold for the antigen to be uptaken and presented by B cells (Batista and Neuberger, 2000) . The other important feature of Qb-VLPs is that they carry nucleic acids that can activate B cell TLR7 or TLR9 signaling (Jegerlehner et al., 2007; Hou et al., 2011) . In this study we showed that B cell MyD88 was required for the differentiation of CD4 + T cells into Tfh and Th1 cells upon Qb-Ova immunization. Sensing innate signals during antigen presentation is also required for DC-mediated antigen presentation (Banchereau and Steinman, 1998; Medzhitov and Janeway, 2002) . However, in contrast to DCs, B cells are mainly sensitive to endosomal TLR signaling and depend on BCR-mediated endocytosis for taking up TLR ligands. This mechanism presumably ensures the simultaneous detection of PAMPs and foreign antigens in B cells, preventing unintentional activation of B cells. Hence, ''multivalency'' and ''endosomal TLR ligands'' of Qb-VLPs may synergistically activate B cells to convert them into fully competent APCs. We have to point out here that not all VLPs contain TLR ligands. For example, both hepatitis B virus (HBV) and human papilloma virus (HPV) vaccines are VLPs without nucleic acids inside (Ludwig and Wagner, 2007) . We predicted that such kinds of ''empty'' VLPs would not be able to take the advantage of B cells for initiating CD4 + T cell activation. Indeed, both vaccines are given with additional adjuvants during clinical practices. The initiation of CD4 + T cell response by antigen-specific B cells upon VLP immunization likely represents an evolutionarily conserved mechanism underlying the humoral responses to viral infections. Most viruses exhibit repetitive subunits on their surface and carry nucleic acids as genetic material that can be sensed by TLRs. We showed here that at least in the case of influenza A virus, antigen-specific B cells could also activate naive CD4 + T cells. However, some viruses exhibit relatively low density of surface proteins, such as human immunodeficiency virus (HIV). Such features may prevent B cells from capturing them efficiently, thus helping their evasion from the immune system. In addition to their roles in anti-viral responses, it has been long speculated that B cells are involved in breaking tolerance in autoimmune diseases. In SLE model, it has been shown that B cells recognizing self-antigens containing TLR ligands could break T cell tolerance (Yan et al., 2006) . Interestingly, when gonadotropin-releasing hormone (GnRH), a selfantigen, was constructed into a VLP platform that was similar to the Qb-VLP, it induced autoimmunity and caused testis reduction in experimental mice (Tissot et al., 2010) . Our data suggested a possible role for B cells in initiating these processes. Therefore, specially designed nanoparticle antigens could potentially be applied not only to prophylactic vaccines against infectious diseases, but also to therapeutic vaccines that are targeted to break established immune tolerance, such as in tumors and chronic infections.
STAR+METHODS
Detailed methods are provided in the online version of this paper and include the following: Labeling and enrichment of Qb-VLP-specific cells Labeling and enrichment of Qb-specific B cells was done as previously described . Qb-FITC or Qb-AF647 was added to enzymatically-dissociated splenocytes at 2 nM and incubated at 4 C for 30min. Cells were then incubated with anti-FITC or anti-Cy5/AF647 microbeads (Miltenyi Biotec) and isolated by magnetic column (Mitenyi Biotec). Qb-GFP was added at 2nM when it is necessary to distinguish Qb+ versus AF647+ B cells.
Induction of oral tolerance WT mice were given ovalbumin in drinking water (4 mg/mL) for seven consecutive days followed by regular water for two days before immunization or adoptive transfer experiments.
Flow cytometry
Cells were suspended and stained in FACS buffer (2% newborn calf serum, 2mM EDTA, 0.1% NaN 3 in PBS). For intracellular staining, cells were treated with Cytofix/Cytoperm solution (BD Biosciences) following the manufacturer's instruction. Antibodies and reagents used for flow cytometry included: AF700 anti-CD4 (RM4-5), AF647 anti-CD4 (RM4-5), BV421 anti-CD90.1 (Thy1.1) (OX-7), PerCPCy5.5 anti-CD44 (IM7), APC anti-CD62L (MEL-14), PE anti-PD-1 (RMP1-30), rat anti-CXCR5 (2G8), AF647 anti-Bcl-6 (K112-91), PE anti-T-BET (4B10), biotin anti-CXCR3 (CXCR3-173), PE-Cy7 anti-CD69 (H1.2F3), PE anti-CD25 (PC61), APC anti-CD11c (N418), PE-CF594 anti-B220 (RA3-6B2), APC-EF780 anti-B220 (RA3-6B2), APC-Cy7 anti-CD19 (1D3), PerCP-Cy5.5 anti-CD8 (53-6.7), PECy7 anti-IgM (R6-60.2), BV711 anti-IgD (11-26c.2a), AF700 anti-MHC-II (M5/114.15.2), PE anti-CD83 (Michel-19), PE anti-CD86 (GL1), biotin anti-CCR7 (4B12), biotin donkey anti-rat IgG, PE-Cy7 streptavidin (eBiosciences). All data were collected on an LSR II cytometer (BD) and analyzed with FlowJo (TreeStar). Gating for activation related markers (including CD44, CD62L, CD69, CD25, CXCR3, CXCR5, Bcl-6, PD-1 and T-BET) was based on the expression of these markers in OT-II T cells from unimmunized mice. All the numbers shown in the flow cytometry plots are the percent of cells from their direct parental group.
Control experiments for Bcl-6 staining is shown in Figures S1E and S1F.
Transcriptome analysis for Qb-specific B cells Naive B cells were sorted from unimmunized mice as B220 + CD19 + cells. Qb-specific cells were sorted from mice immunized 2 or 3 days before. Splenocytes were first enriched with Qb-AF647 and anti-AF647 magnetic beads. The enriched cell fraction was further sorted for Qb-specific B cells as Qb-AF647 + Qb-GFP + B220 + CD19 + or Qb-specific PCs as Qb-AF647 + Qb-GFP + B220 -CD19 -. Total RNA from at least 50,000 isolated mouse B cells were extracted by Trizol (Life Technology) and precipitated by RNase-free glycogen (Life technology), then mRNAs were immediately isolated from total RNA with NEBNextÒ Poly(A) mRNA Magnetic Isolation Module (E7490S). High throughput sequencing library was constructed with NEBNextÒ Ultra II RNA Library Prep Kit for IlluminaÒ (E7770S). Quality checking of the sequencing library was performed by Annoroad Gene Technology Co. Ltd. and BerryGenomics Co. Ltd. and sequenced on Illumina HiSeq X10 and Illumina Nova-Seq platforms with PE150 policy, respectively.
Raw sequencing reads were assessed with FASTQC and mapped to mouse genome (GENCODE M12, mm10) with STAR aligner (v2.5.2b). Based on the above alignments, Cuffdiff (v2.2.1 4237) were used to quantify the FPKM values and p values for gene transcription differences, during which 3 biological replicates were used for each treatment/cell type. For gene sets that we used, MHC class II antigen presentation related genes were adopt from GSEA MSigDB M705, and other used gene sets were adopt from gene family information in HGNC Database (HUGO Gene Nomenclature Committee (HGNC), EMBL Outstation -Hinxton, European Bioinformatics Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SD, UK www.genenames.org). FPKM values of gene sets were first hierarchically clustered with Cluster v3.0 (average linkage clustering) and visualized with Java TreeView (v1.1) for transcription heatmaps.
QUANTIFICATION AND STATISTICAL ANALYSIS Quantification of proliferation Index
The proliferation index is calculated as log (F Ind /MFI)/log(2); F Ind is the fluorescence intensity of CFSE in undivided cells; MFI is the median fluorescence intensity of CFSE in all OT-II CD4 + T cells.
Statistical Analysis
Unpaired Student's t test was performed for statistical analysis.
DATA AND SOFTWARE AVAILABILITY
RNA-sequencing raw data have been deposited in the Gene Expression Omnibus (GEO) under accession number GEO: 112351.
